格隆汇10月9日丨金城医药（维权）(300233.SZ)公布，全资子公司北京金城泰尔制药有限公司于近日收 到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，化学原料药名称：克立硼罗。克立 硼罗是一种磷酸二酯酶4（PDE-4）抑制剂，其制剂克立硼罗软膏适用于3月龄及以上轻度至中度特应性 皮炎患者的局部外用治疗。 ...

智通财经APP讯，金城医药(300233.SZ)发布公告，公司之全资子公司北京金城泰尔制药有限公司于近日 收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》。 克立硼罗是一种磷酸二酯酶4(PDE-4)抑制剂，其制剂克立硼罗软膏适用于3月龄及以上轻度至中度特应 性皮炎患者的局部外用治疗。目前国内有22家企业克立硼罗原料药登记状态为A。根据IMS数据信息， 2022年到2024年克立硼罗制剂全球销售额分别是2.24亿美元、2.06亿美元、1.96亿美元，原料药消耗量 分别是706.68公斤、963.57公斤、1118.43公斤。 ...

智通财经APP讯，金城医药(300233.SZ)发布公告，公司之全资子公司北京金城泰尔制药有限公司于近日 收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》。 克立硼罗是一种磷酸二酯酶4(PDE-4)抑制剂，其制剂克立硼罗软膏适用于3月龄及以上轻度至中度特应 性皮炎患者的局部外用治疗。目前国内有22家企业克立硼罗原料药登记状态为A。根据IMS数据信息， 2022年到2024年克立硼罗制剂全球销售额分别是2.24亿美元、2.06亿美元、1.96亿美元，原料药消耗量 分别是706.68公斤、963.57公斤、1118.43公斤。 ...

Group 1 - The company achieved a revenue of 1.79 billion yuan in the raw materials and additives business during the first half of the year, with hyaluronic acid raw material sales reaching 1.16 billion yuan, a year-on-year increase of 23.4% [3] - The pharmaceutical business generated a revenue of 207 million yuan, with over 200 new county-level and OTC customer developments, focusing on core product upgrades [2] - The cosmetics segment reported a revenue of 1.094 billion yuan, with the Yilian brand achieving a revenue of 554 million yuan, reflecting a year-on-year growth of 23.78% [2] Group 2 - The company launched over 80 new products in the cosmetics sector, including the "Yier Doctor 287 mask" and "Yilian Purple Light Dual Extract Essence Water" [3] - The company has made significant advancements in technology, such as the innovative permeable collagen technology, which increased collagen subcutaneous penetration by 27.5 times [3] - The company is actively developing the "food and medicine homologous" business and has established cooperation with major clients to enhance raw material supply [2]